Cargando…

Platinum-Based Neoadjuvant Chemotherapy for Breast Cancer With BRCA Mutations: A Meta-Analysis

BACKGROUND: Triple-negative breast cancer (TNBC) is one of the most aggressive subtypes of breast cancer and the major phenotype of BRCA related hereditary breast cancer. Platinum is a promising chemotherapeutic agent for TNBC. However, its efficacy for breast cancer with BRCA germline mutation rema...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Chang-Jun, Xu, Ying, Lin, Yan, Zhu, Han-Jiang, Zhou, Yi-Dong, Mao, Feng, Zhang, Xiao-Hui, Huang, Xin, Zhong, Ying, Sun, Qiang, Li, Cheng-Gang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693629/ https://www.ncbi.nlm.nih.gov/pubmed/33304851 http://dx.doi.org/10.3389/fonc.2020.592998

Ejemplares similares

The effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers -systematic review and meta-analysis
por: Caramelo, Olga, et al.
Publicado: (2019)

Role of BRCA Mutations in the Modulation of Response to Platinum Therapy
por: Mylavarapu, Sanghamitra, et al.
Publicado: (2018)

Complete Pathological Response to Platinum-Based Neoadjuvant Chemotherapy in BRCA2-Associated Locally Advanced Pancreatic Cancer: A Case Report and Literature Review
por: Asiri, Mohamed S, et al.
Publicado: (2023)

Efficacy and Safety of Albumin-Bound Paclitaxel Compared to Docetaxel as Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer
por: Lv, Zhi-Dong, et al.
Publicado: (2022)

Effects of Neoadjuvant Chemotherapy in Ovarian Cancer Patients With Different Germline BRCA1/2 Mutational Status: A Retrospective Cohort Study
por: Fu, Mengdi, et al.
Publicado: (2022)

Metabolic Syndrome Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
por: Lu, Ying, et al.
Publicado: (2022)

Meta-Analysis of Shrinkage Mode After Neoadjuvant Chemotherapy for Breast Cancers: Association With Hormonal Receptor
por: Zheng, Chun-Hui, et al.
Publicado: (2022)

Platinum-based neoadjuvant chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis
por: Li, Zhen-Yu, et al.
Publicado: (2020)

Effect and Safety of Therapeutic Regimens for Patients With Germline BRCA Mutation-Associated Breast Cancer: A Network Meta-Analysis
por: Jiang, Ying, et al.
Publicado: (2021)

Platinum-based neoadjuvant chemotherapy in BRCA1-positive breast cancer: a retrospective cohort analysis and literature review
por: Sæther, Nikolai Havn, et al.
Publicado: (2018)

BRCA1-methylated triple negative breast cancers previously exposed to neoadjuvant chemotherapy form RAD51 foci and respond poorly to olaparib
por: Velazquez, Carolina, et al.
Publicado: (2023)

Body composition change during neoadjuvant chemotherapy for breast cancer
por: Jang, Min Kyeong, et al.
Publicado: (2022)

BRCA-mutated gastric adenocarcinomas are associated with chromosomal instability and responsiveness to platinum-based chemotherapy
por: Oh, Ji Hyun, et al.
Publicado: (2023)

ABTB2 Regulatory Variant as Predictor of Epirubicin-Based Neoadjuvant Chemotherapy in Luminal A Breast Cancer
por: Gong, Yajie, et al.
Publicado: (2020)

PET/CT-based radiomics analysis may help to predict neoadjuvant chemotherapy outcomes in breast cancer
por: Yang, Liping, et al.
Publicado: (2022)

Genetic Polymorphisms and Platinum-Based Chemotherapy-Induced Toxicities in Patients With Lung Cancer: A Systematic Review and Meta-Analysis
por: Liu, Wenhui, et al.
Publicado: (2020)

Neoadjuvant chemotherapy with Cisplatin in BRCA1 mutation carriers – results of treatment
por: Byrski, T, et al.
Publicado: (2012)

Markers Associated With Tumor Recurrence in Patients With Breast Cancer Achieving a Pathologic Complete Response After Neoadjuvant Chemotherapy
por: Xie, Li-Yun, et al.
Publicado: (2022)

Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors
por: O’Sullivan, Ciara C., et al.
Publicado: (2014)

Breast-conserving surgery versus mastectomy for treatment of breast cancer after neoadjuvant chemotherapy
por: Song, Yu-Chun, et al.
Publicado: (2023)

A Decision-Making Supporting Prediction Method for Breast Cancer Neoadjuvant Chemotherapy
por: Song, Dong, et al.
Publicado: (2021)

Molecular Trajectory of BRCA1 and BRCA2 Mutations
por: Hatano, Yuichiro, et al.
Publicado: (2020)

Advances in Imaging in Evaluating the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer
por: Kong, Xianshu, et al.
Publicado: (2022)

Platinum-Based Chemotherapy and Immunotherapy in Early Triple-Negative Breast Cancer: A Meta-Analysis and Indirect Treatment Comparison
por: He, Qin, et al.
Publicado: (2021)

Breast microbiome associations with breast tumor characteristics and neoadjuvant chemotherapy: A case-control study
por: Li, Xuejun, et al.
Publicado: (2022)

Role of neutrophil-to-lymphocyte ratio as a prognostic biomarker in patients with breast cancer receiving neoadjuvant chemotherapy: a meta-analysis
por: Zhou, Qiong, et al.
Publicado: (2021)

Platinum-Based Neoadjuvant Chemotherapy Before Radical Prostatectomy for Locally Advanced Prostate Cancer With Homologous Recombination Deficiency: A Case Report
por: Zhuang, Junlong, et al.
Publicado: (2022)

Contrast-Enhanced Spectral Mammography-Based Radiomics Nomogram for the Prediction of Neoadjuvant Chemotherapy-Insensitive Breast Cancers
por: Wang, Zhongyi, et al.
Publicado: (2021)

Efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy in locally advanced esophageal cancer: A meta-analysis
por: Wang, Jincheng, et al.
Publicado: (2022)

Identification of Ovarian Cancer Patients Most Likely to Achieve Chemotherapy Response Score 3 Following Neoadjuvant Chemotherapy: Development of a Predictive Nomogram
por: Liang, Wei-feng, et al.
Publicado: (2020)

Mutations of BRCA1, BRCA2, and PALB2 Genes in Breast Tumor Tissue: Relationship with the Effectiveness of Neoadjuvant Chemotherapy and Disease Prognosis
por: Tsyganov, Matvey M., et al.
Publicado: (2023)

Survival and complications after neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for locally advanced gastric cancer: a systematic review and meta-analysis
por: Zhu, Youqi, et al.
Publicado: (2023)

The Diagnostic Performance of DCE-MRI in Evaluating the Pathological Response to Neoadjuvant Chemotherapy in Breast Cancer: A Meta-Analysis
por: Cheng, Qingqing, et al.
Publicado: (2020)

Multiomics technologies for comprehensive tumor microenvironment analysis in triple-negative breast cancer under neoadjuvant chemotherapy
por: Wang, Gang, et al.
Publicado: (2023)

Genomic Profiling Comparison of Germline BRCA and Non-BRCA Carriers Reveals CCNE1 Amplification as a Risk Factor for Non-BRCA Carriers in Patients With Triple-Negative Breast Cancer
por: Huang, Xin, et al.
Publicado: (2020)

Editorial: Recent advancements in neoadjuvant chemotherapy for specific breast cancer subtypes
por: Adham, Sirin A., et al.
Publicado: (2022)

Neoadjuvant chemotherapy for breast cancer: an evaluation of its efficacy and research progress
por: Chen, Yushi, et al.
Publicado: (2023)

A systematic review and meta-analysis of BRCA1/2 mutation for predicting the effect of platinum-based chemotherapy in triple-negative breast cancer
por: Jia, Xiaomeng, et al.
Publicado: (2022)

An Immune Model to Predict Prognosis of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy Based on Support Vector Machine
por: Wang, Mozhi, et al.
Publicado: (2021)

Neoadjuvant and Adjuvant Chemotherapy for Variant Histology Bladder Cancers: A Systematic Review and Meta-Analysis
por: Zhu, Ziwei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_v2538br7e25qb3avbbjsguh1fj